NNB Nutrition files patent for MitoBurn
The patent is for improving endurance and reducing fatigue during workout for pre and post workout product applications.
Photo © iStockphoto.com/Ibrakovic
NNB Nutrition (Nanjing, China) filed a PCT patent (PCT/CN2021/087159) for the benefits of MitoBurn, a registered trademark L-BAIBA, or β-aminoisobutyric acid. The patent is for improving endurance and reducing fatigue during workout and when supplementing BAIBA daily for a period pre- /post-exercise. The ingredient does so by promoting glycogen synthase activity and augementing glycogen storage capability, particularly in muscle and liver tissue. Gylcogen is the main source of fuel for skeletal muscle tissue during exercise.
“With this new invention of MitoBurn, we believe we’ll make a huge change to the pre- & post-workout market by offering an unprecedented ingredient option with intellectual property protection to our partners who are committed to make innovative supplements for customers.” Kylin Liao, founder and CEO of NNB Nutrition, said in the press release.
According to NNB, the claims for MitoBurn include:
- Decrease body fat and improve body composition
- Shown in research to improve carb tolerance and insulin sensitivity
- Enhances the body’s exercise signal to intensify exercise efforts
- Promotes anti-aging, mitochondrial function, and cellular energy benefits
- Increases ketones, promoting cognition, reduced appetite, and muscle protection.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
